Search

Your search keyword '"Chronic obstructive lung disease -- Care and treatment"' showing total 99 results
Start Over Descriptor "Chronic obstructive lung disease -- Care and treatment" Topic general interest
99 results on '"Chronic obstructive lung disease -- Care and treatment"'

1. HELPING CANADIANS MANAGE LUNG DISEASE ONE BREATH AT A TIME

Author

Connors, Cheryl

Subjects
Allied health personnel -- Practice, Chronic obstructive lung disease -- Care and treatment, Education, Lung diseases, Spirometry, Respiratory tract diseases, Asthma, General interest, News, opinion and commentary
Abstract

John learned that he had COPD (chronic obstructive pulmonary disease) after taking a breathing test called spirometry at the Toronto Western Hospital's Asthma and Airway Centre. His respirologist, Dr. Ken [...]

Published
2019

2. AstraZeneca PLC - AZN - Trixeo Aerosphere approved in the EU for COPD

Subjects
London Stock Exchange PLC, Securities industry, Chronic obstructive lung disease -- Care and treatment, Drug approval, Securities industry, General interest, News, opinion and commentary, European Union
Abstract

London: London Stock Exchange plc has issued the following announcement: AstraZenecaOs Trixeo Aerosphere (formoterol fumarate/glycopyrronium bromide/budesonide) has been approved in the European Union (EU) for maintenance treatment in adult patients [...]

Published
2020

3. Philips expands its home care portfolio for COPD patients with first-of-its-kind non-invasive ventilator

Subjects
Philips Gloeilampenfabrieken N.V., Home care, Chronic obstructive lung disease -- Care and treatment, Electronics industry, Electronics industry, General interest, News, opinion and commentary
Abstract

Netherlands: Koninklijke Philips N.V. has issued the following news release: Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the launch of Philips Ventilator BiPAP [...]

Published
2020

4. AstraZeneca PLC - AZN - Trixeo Aerosphere receives positive CHMP opinion

Subjects
AstraZeneca PLC, London Stock Exchange PLC, Securities industry, Chronic obstructive lung disease -- Care and treatment, Respiratory system agents, Pharmaceutical industry, Securities industry, General interest, News, opinion and commentary, European Union
Abstract

London: London Stock Exchange plc has issued the following announcement: Trixeo Aerosphere recommended for approval in the EU by CHMP for the maintenance treatment of COPD Recommendation of triple-combination therapy [...]

Published
2020

5. PAOG Expands Cannabis Pharma Treatment Research

Subjects
Marijuana, Chronic obstructive lung disease -- Care and treatment, Respiratory system agents, General interest, News, opinion and commentary
Abstract

Sandusky: PAO Group, Inc. has issued the following news release: PAO Group, Inc. (OTC Pink: PAOG) today announced the company will expand its cannabis pharmaceutical treatment research beyond its current [...]

Published
2020

6. Verona Pharma PLC - VRP - Verona Pharma Announces Publication of Phase 2b COPD Symptom Data in the International Journal of Chronic Obstructive Pulmonary Disease

Subjects
London Stock Exchange PLC -- Product development, Clinical trials, Securities industry -- Product development, Tiotropium -- Product development, Chronic obstructive lung disease -- Care and treatment, Trade journals -- Product development, Securities industry, General interest, News, opinion and commentary
Abstract

London: London Stock Exchange plc has issued the following announcement: Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) ('Verona Pharma'), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces publication of [...]

Published
2020

7. Verona To Trial Ensifentrine For Covid-19; First Half Loss Widens

Subjects
Chronic obstructive lung disease -- Care and treatment, Medical research, COVID-19 -- Care and treatment, General interest, News, opinion and commentary
Abstract

London: Verona Pharma PLC has issued the following press release: Verona Pharma PLC on Friday said the impact of Covid-19 on clinical trials in the first half has been limited, [...]

Published
2020

8. PAOG Cannabis Pharma Initiative Stands to Benefit From Senator Marco Rubio and Congresswoman Jenniffer Gonzalez Colon New Bill

Subjects
United States. Food and Drug Administration, Congressional representatives, Marijuana, Chronic obstructive lung disease -- Care and treatment, Drug approval, General interest, News, opinion and commentary
Abstract

SANDUSKY: PAO Group, Inc. has issued the following press release: PAO Group, Inc. (USOTC: PAOG) today announced that the company's ongoing business development initiative in Puerto Rico could benefit from [...]

Published
2020

9. AstraZeneca's Breztri Aerosphere Gets US Approval In COPD

Subjects
AstraZeneca PLC, Chronic obstructive lung disease -- Care and treatment, Pharmaceutical industry, Drug approval, General interest, News, opinion and commentary
Abstract

London: AstraZeneca PLC has issued the following press release: AstraZeneca PLC on Friday said Breztri Aerosphere has been approved by the US Food & Drug Administration for the maintenance treatment [...]

Published
2020

10. PT010 Significantly Reduced Rate of Moderate or Severe COPD Exacerbations in Phase III ETHOS Trial

Subjects
AstraZeneca PLC -- Product development, Clinical trials, Chronic obstructive lung disease -- Care and treatment, Respiratory system agents, Pharmaceutical industry -- Product development, General interest, News, opinion and commentary
Abstract

WILMINGTON: AstraZeneca has issued the following press release: Full results from the positive Phase III ETHOS trial showed AstraZeneca's triple-combination therapy PT010 (budesonide/glycopyrronium/formoterol fumarate) demonstrated a statistically significant reduction in [...]

Published
2020

11. Breztri Aerosphere significantly reduced rate of moderate or severe COPD exacerbations in Phase III ETHOS trial

Subjects
AstraZeneca PLC -- Product development, Clinical trials, Chronic obstructive lung disease -- Care and treatment, Pharmaceutical industry -- Product development, General interest, News, opinion and commentary, Bevespi Aerosphere (Medication) -- Product development
Abstract

Cambridge: AstraZeneca PLC (AZNCF) has issued the following press release: Full results from the positive Phase III ETHOS trial showed AstraZeneca's triple-combination therapy Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate) demonstrated a statistically [...]

Published
2020

12. Get the right treatment for your pulmonary and sleep problems!

Subjects
Lung cancer -- Care and treatment, Sleep, Chronic obstructive lung disease -- Care and treatment, Sleep apnea -- Care and treatment, Hypertension, Pulmonary fibrosis, Lung diseases, Health, Apnea, Respiratory tract diseases, Asthma, Diseases, Pulmonary hypertension, Physicians, Fibrosis, Sleep disorders, General interest
Abstract

India, June 10 -- The physicians associated with the center provide treatment for wide range of pulmonary and sleep conditions that include chronic obstructive pulmonary disease (COPD), pleural disease, lung [...]

Published
2020

13. Forthcoming and Available Therapies for Allergy, Infectious Diseases and COVID-19

Subjects
Reslizumab, Marburg virus disease -- Care and treatment, Lassa fever -- Care and treatment, Benralizumab, Chronic obstructive lung disease -- Care and treatment, Atopic dermatitis -- Care and treatment, Communicable diseases -- Care and treatment, Medical research, Lopinavir, Omalizumab, Lung diseases, Rhinitis, Anaphylaxis, Antihistamines, Respiratory tract diseases, Asthma, Hives (Disease), Diseases, Eczema, Technology, Corticosteroid drugs, Dermatitis, General interest, News, opinion and commentary
Abstract

DUBLIN: Research and Markets has issued the following news release: The 'Technology Breakthroughs Driving Allergy & Infectious Disease Therapy' report has been added to ResearchAndMarkets.com's offering. The current research study [...]

Published
2020

14. AstraZeneca PLC - AZN Bevespi Aerosphere approved in China for COPD

Subjects
AstraZeneca PLC, London Stock Exchange PLC, Securities industry, Chronic obstructive lung disease -- Care and treatment, Respiratory system agents, Pharmaceutical industry, Medical supplies, Stock offerings, Stock exchanges, Emphysema, Lung diseases, Bronchitis, Diseases, Securities industry, General interest, News, opinion and commentary, Bevespi Aerosphere (Medication)
Abstract

London: London Stock Exchange plc has issued the following announcement: Bevespi Aerosphere approved in China for patients with COPD First approval in China of a fixed-dose, long-acting dual bronchodilator in [...]

Published
2020

15. Verona Pharma PLC - VRP Verona Pharma Announces FDA Response to End-of-Phase 2 Briefing Package for Ensifentrine in COPD and Outlines Phase 3 ENHANCE Clinical Program

Subjects
United States. Food and Drug Administration -- Planning, London Stock Exchange PLC -- Planning, Chronic obstructive lung disease -- Care and treatment, Stock offerings, Stock exchanges, Lung diseases, Diseases, Company business planning, General interest, News, opinion and commentary
Abstract

London: London Stock Exchange plc has issued the following announcement: Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) ('Verona Pharma'), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it [...]

Published
2020

16. Verona Pharma Announces Publication of Key Phase 2b COPD Data in Respiratory Research

Subjects
Clinical trials, Tiotropium -- Product development, Chronic obstructive lung disease -- Care and treatment, Lung diseases, Diseases, General interest, News, opinion and commentary
Abstract

LONDON: Verona Pharma plc has issued the following press release: Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) ('Verona Pharma'), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces publication of [...]

Published
2020

17. Commerical feature

Subjects
Chronic obstructive lung disease -- Care and treatment, Respiratory equipment -- Innovations, General interest, News, opinion and commentary
Abstract

One promising new technology that has been extending care to the home for some COPD patients is Oscillating Positive Expiratory Pressure (OPEP) therapy. An OPEP device is a drug-free treatment, [...]

Published
2016

18. Many COPD Patients Struggle To Pay For Each Breath

Subjects
Health care costs -- Social aspects, Chronic obstructive lung disease -- Care and treatment, Inhalers -- Prices and rates -- Usage, Company pricing policy, General interest
Abstract

To listen to this broadcast, click here: http://www.npr.org/templates/story/story.php?storyId=529759280 BYLINE: SARAH JANE TRIBBLE HOST: ROBERT SIEGEL ROBERT SIEGEL: COPD, or chronic obstructive pulmonary disease, is one of the most common illnesses [...]

Published
2017

19. KALY- Kali-Extracts Proprietary CBD Extract Could Offer Coronavirus Relief

Subjects
Chronic obstructive lung disease -- Care and treatment, Marijuana, Lung diseases, Nonprescription drugs, Diseases, General interest, News, opinion and commentary
Abstract

Dallas: Kali-Extracts, Inc. has issued the following press release: Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (OTC Pink: KALY) ('KALY') today confirmed efforts to evaluate its proprietary CBD extract formulation as [...]

Published
2020

20. KALY-Kali-Extracts RespRx Could Offer Treatment for Coronavirus Symptoms

Subjects
Chronic obstructive lung disease -- Care and treatment, Marijuana, Lung diseases, Diseases, General interest, News, opinion and commentary
Abstract

DALLAS: Kali-Extracts, Inc. has issued the following press release: Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) ('KALY') today highlighted that its RespRx CBD formulation could offer treatment for coronavirus [...]

Published
2020

21. Verona Pharma boosts 59% premarket on successful ensifentrine data

Subjects
Tiotropium, Chronic obstructive lung disease -- Care and treatment, Lung diseases, Clinical trials, Medical research, Respiratory tract diseases, General interest, News, opinion and commentary
Abstract

Verona Pharma (NASDAQ:VRNA) perks up 59% premarket on modest volume in reaction to positive results from a Phase 2b clinical trial evaluating lead drug ensifentrine for the treatment of chronic [...]

Published
2020

22. AstraZeneca PLC - AZN Triple-combination approved in China for COPD

Subjects
AstraZeneca PLC, London Stock Exchange PLC, Securities industry, Chronic obstructive lung disease -- Care and treatment, Respiratory system agents, Pharmaceutical industry, Medical supplies, Stock offerings, Stock exchanges, Technology, Lung diseases, Securities industry, General interest, News, opinion and commentary, Bevespi Aerosphere (Medication)
Abstract

London: London Stock Exchange plc has issued the following announcement: AstraZeneca's triple-combination therapy approved in China for patients with COPD First fixed-dose triple-combination therapy in a pressurised metered-dose inhaler device [...]

Published
2019

23. AstraZeneca's triple-combination therapy approved in China for patients with COPD

Subjects
AstraZeneca PLC, Chronic obstructive lung disease -- Care and treatment, Respiratory system agents, Pharmaceutical industry, Medical supplies, Technology, Lung diseases, General interest, News, opinion and commentary
Abstract

Cambridge, United Kingdom: AstraZeneca Pharmaceutical company has issued the following press release: AstraZeneca today announced that budesonide/glycopyrronium/formoterol fumarate has been approved in China for the maintenance treatment of chronic obstructive [...]

Published
2019

24. ALung Announces Continued Progress Towards Completion of Two Landmark Pivotal Trials

Subjects
Chronic obstructive lung disease -- Care and treatment, Adult respiratory distress syndrome -- Care and treatment, Death, Technology, Cardiovascular diseases, Respiratory insufficiency, Clinical trials, General interest, News, opinion and commentary
Abstract

PITTSBURGH: ALung Technologies, Inc. has issued the following press release: ALung Technologies, Inc., the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory [...]

Published
2019

25. Footit Medical Grows Its Fisher & Paykel Optiflow High Flow Therapy Airvo 2 Line for COPD Patients

Subjects
Chronic obstructive lung disease -- Care and treatment, Medical equipment, Medical supplies, General interest, News, opinion and commentary
Abstract

WEST SPRINGFIELD: Footit Medical Supply, Inc. has issued the following press release: Footit Medical Supply, Inc a durable Medical Equipment, Mobility, & Respiratory provider, announced that it will be focusing [...]

Published
2019

26. Bayer, Brigham and Women's Hospital, Massachusetts General Hospital open joint lab for research of new treatments for chronic lung diseases

Subjects
Bayer AG, Chronic obstructive lung disease -- Care and treatment, Pharmaceutical industry, Scientists, Lung diseases, Respiratory tract diseases, General interest, News, opinion and commentary, Massachusetts General Hospital
Abstract

BERLIN: Bayer has issued the following press release: Bayer and Partners HealthCare's founding members Brigham and Women's Hospital (BWH) and Massachusetts General Hospital (MGH) today announced the launch of a [...]

Published
2019

27. Bayer, Brigham and Women's Hospital, and Massachusetts General Hospital open joint lab for research of new treatments for chronic lung diseases

Subjects
Bayer AG, Chronic obstructive lung disease -- Care and treatment, Pharmaceutical industry, Scientists, Lung diseases, Respiratory tract diseases, General interest, News, opinion and commentary, Massachusetts General Hospital
Abstract

Germany: Bayer AG has issued the following press release: Bayer and Partners HealthCare's founding members Brigham and Women's Hospital (BWH) and Massachusetts General Hospital (MGH) today announced the launch of [...]

Published
2019

28. Breztri Aerosphere Phase III ETHOS trial met its primary endpoint in chronic obstructive pulmonary disease

Subjects
AstraZeneca PLC -- Product development, Clinical trials, Chronic obstructive lung disease -- Care and treatment, Pharmaceutical industry -- Product development, Neurophysiology, Lung diseases, General interest, News, opinion and commentary, Bevespi Aerosphere (Medication)
Abstract

Cambridge: AstraZeneca PLC (AZNCF) has issued the following press release: AstraZeneca today announced positive results from the Phase III ETHOS trial for triple-combination therapy Breztri Aerosphere, formerly PT010, in patients [...]

Published
2019

29. PT010 Phase III ETHOS trial met its primary endpoint in chronic obstructive pulmonary disease

Subjects
AstraZeneca PLC -- Product development, Clinical trials, Chronic obstructive lung disease -- Care and treatment, Pharmaceutical industry -- Product development, Lung diseases, General interest, News, opinion and commentary
Abstract

WILMINGTON: AstraZeneca has issued the following press release: AstraZeneca today announced positive results from the Phase III ETHOS trial for triple-combination therapy PT010 in patients with moderate to very severe [...]

Published
2019

30. ALung Announces the Achievement of a Key Milestone in the U.S. Based VENT-AVOID Trial and Continued Progress Towards Completion of the Trial

Subjects
Mortality, Chronic obstructive lung disease -- Care and treatment, Adult respiratory distress syndrome -- Care and treatment, Death, Morbidity, Heart diseases, Technology, Cardiovascular diseases, Respiratory insufficiency, Clinical trials, General interest, News, opinion and commentary
Abstract

PITTSBURGH: ALung Technologies, Inc. has issued the following press release: ALung Technologies, Inc., the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory [...]

Published
2019

31. Medovex's Transition to H-CYTE Underscores Biotechnology Focus

Subjects
Biotechnology, Chronic obstructive lung disease -- Care and treatment, Anti-inflammatory agents, Death, Technology, Lung diseases, Backup software, Respiratory tract diseases, General interest, News, opinion and commentary
Abstract

Georgia: has issued the following press release: Medovex Corp. (OTCQB: Symbol MDVX) ('Medovex' or the 'Company'), is transitioning to its new name H-CYTE Inc. ('H-CYTE') to underscore its focus of [...]

Published
2019

32. Bevespi Aerosphere approved by the Japanese Ministry of Health, Labour and Welfare for patients with chronic obstructive pulmonary disease

Subjects
AstraZeneca PLC, Chronic obstructive lung disease -- Care and treatment, Respiratory system agents, Pharmaceutical industry, Technology, Lung diseases, Health, Respiratory tract diseases, General interest, News, opinion and commentary, Bevespi Aerosphere (Medication)
Abstract

Stockholm: AstraZeneca has issued the following press release: AstraZeneca today announced that Bevespi Aerosphere (glycopyrronium/formoterol fumarate) has been approved in Japan as a fixed-dose, long-acting dual bronchodilator to relieve symptoms [...]

Published
2019

33. Breztri Aerosphere (PT010) approved in Japan for patients with chronic obstructive pulmonary disease

Subjects
AstraZeneca PLC, Chronic obstructive lung disease -- Care and treatment, Respiratory system agents, Pharmaceutical industry, Technology, Lung diseases, Formoterol, Health, Respiratory tract diseases, General interest, News, opinion and commentary
Abstract

Stockholm: AstraZeneca has issued the following press release: AstraZeneca today announced that Breztri Aerosphere (budesonide/glycopyrronium/ formoterol fumarate), formerly PT010, has been approved in Japan as a triple-combination therapy to relieve [...]

Published
2019

34. First patients successfully treated in the Nuvaira AIRFLOW-3 COPD pivotal trial

Subjects
Chronic obstructive lung disease -- Care and treatment, Bronchoscopy, Hyperactivity, Lung diseases, Clinical trials, Denervation, Novels, General interest, News, opinion and commentary, Temple University Hospital
Abstract

MINNEAPOLIS: Nuvaira has issued the following press release: Nuvaira, developer of novel therapeutic strategies to treat obstructive lung diseases, announced the first treatments in the AIRFLOW-3 pivotal trial, the first [...]

Published
2019

35. KALY - Kali-Extracts, Inc. Publishes Cannabis Extract Lung Disease Treatment Study Preview

Subjects
Chronic obstructive lung disease -- Care and treatment, Medical research, Respiratory system agents, Marijuana, Lung diseases, Primates, Genomics, Patents, Public health, Health, Genetic research, General interest, News, opinion and commentary
Abstract

DALLAS: Kali, Inc. has issued the following press release:Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) ('KALY') today published a preview of the recently announced long-term, pilot study on the [...]

Published
2019

36. Barbara Bush, former first lady, turns to 'comfort care'

Author

Johnson, Carolyn Y.

Subjects
Politicians' spouses -- Health aspects, Palliative care, Chronic obstructive lung disease -- Care and treatment, Congestive heart failure -- Care and treatment, General interest, News, opinion and commentary
Abstract

Byline: Carolyn Y. Johnson Barbara Bush, the 92-year-old former first lady of the United States, is in failing health and will not seek further medical care, according to the office [...]

Published
2018

37. CHMP issues a positive opinion for Bevespi Aerosphere for the treatment of chronic obstructive pulmonary disease

Subjects
AstraZeneca PLC, Chronic obstructive lung disease -- Care and treatment, Respiratory system agents, Pharmaceutical industry, General interest, News, opinion and commentary, Bevespi Aerosphere (Medication)
Abstract

Cambridge: AstraZeneca PLC (AZNCF) has issued the following press release: AstraZeneca today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted [...]

Published
2018

39. Triple dual therapy significantly improves lung function, quality of life in COPD patients

Subjects
Chronic obstructive lung disease -- Care and treatment, Medical societies, Respiratory system agents, Medical research, General interest, News, opinion and commentary
Abstract

SAN ANTONIO: American College of Chest Physicians has issued the following press release: The InforMing the PAthway of COPD Treatment (IMPACT) study was conducted to assess the benefits of triple [...]

Published
2018

40. Rockpointe and American Lung Association Offer Much-Needed COPD Education

Subjects
Chronic obstructive lung disease -- Care and treatment, Medical personnel, Associations, General interest, News, opinion and commentary
Abstract

LONG BEACH, : Rockpointe Corporation has issued the following press release: The American Lung Association, in partnership with Rockpointe Corporation and the Potomac Center for Medical Education (PCME), will hold [...]

Published
2018

41. Verona Pharma plc - VRP Verona Pharma Announces Publication of Key Paper on RPL554 in COPD in the European Respiratory Journal (Updated 06-Sep 2018)

Subjects
Chronic obstructive lung disease -- Care and treatment, Medical research, General interest, News, opinion and commentary
Abstract

London: Verona Pharma plc has issued the following press release: Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) ('Verona Pharma' or the 'Company'), a clinical-stage biopharmaceutical company focused on developing and [...]

Published
2018

42. Circassia Pharmaceuticals Plc - CIR Regulatory Application (Updated 13-Aug 2018)

Subjects
United States. Food and Drug Administration, AstraZeneca PLC, Chronic obstructive lung disease -- Care and treatment, Pharmaceutical industry, General interest, News, opinion and commentary
Abstract

London: Circassia Pharmaceuticals Plc has issued the following press release: Circassia Pharmaceuticals plc ('Circassia' or 'the Company'; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces that [...]

Published
2018

43. Respinova Wins Chiesi Spain and Richi Entrepreneurs Second Call

Subjects
Entrepreneurs, Chronic obstructive lung disease -- Care and treatment, Respiratory system agents, General interest, News, opinion and commentary
Abstract

Herzliya: Respinova Ltd. has issued the following press release: Respinova, a Herzliya, Israel-based clinical-stage medical device company developing the novel, non-invasive PulseHalera technology, today announced that it has won the [...]

Published
2018

44. China's health facilities receive 8.18 billion patient visits in 2017

Subjects
Health facilities -- Rankings, Chronic obstructive lung disease -- Care and treatment, Medical care quality, Business, general, General interest, News, opinion and commentary
Abstract

BEIJING, June 9, 2018 (Xinhua via COMTEX) -- Chinese health facilities provided diagnosis and treatments for 8.18 billion patient visits in 2017, increasing by 3.2 percent year on year, according [...]

Published
2018

45. Circassia Pharmaceuticals Plc - CIR US Filing of Duaklir NDA & Tudorza Supplement NDA (Updated 01 June 2018)

Subjects
United States. Food and Drug Administration, AstraZeneca PLC, Chronic obstructive lung disease -- Care and treatment, Pharmaceutical industry, Prescriptions (Drugs), General interest, News, opinion and commentary
Abstract

London: Circassia Pharmaceuticals Plc has issued the following news release: Circassia Pharmaceuticals plc ('Circassia' or 'the Company'; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces the [...]

Published
2018

46. GlaxoSmithKline Seeks Approval For Trelegy Ellipta In Japan

Subjects
GlaxoSmithKline PLC, Chronic obstructive lung disease -- Care and treatment, Respiratory system agents, Pharmaceutical industry, General interest, News, opinion and commentary, Trelegy Ellipta (Medication)
Abstract

London: GlaxoSmithKline PLC has issued the following press release: GlaxoSmithKline PLC and Innoviva Inc said Tuesday they have filed a new drug application with the Japanese health ministry for lung [...]

Published
2018

47. AstraZeneca provides update on GALATHEA Phase III trial for Fasenra in chronic obstructive pulmonary disease

Subjects
AstraZeneca PLC -- Product development, Clinical trials, Chronic obstructive lung disease -- Care and treatment, Pharmaceutical industry -- Product development, General interest, News, opinion and commentary, Fasenra (Medication)
Abstract

Cambridge: AstraZeneca PLC (AZNCF) has issued the following press release: AstraZeneca and MedImmune, its global biologics research and development arm, today announced top-line results from the GALATHEA Phase III trial [...]

Published
2018

48. Mountainside Medical Group Adds New Physicians

Subjects
Physicians, Chronic obstructive lung disease -- Care and treatment, Health care industry, Health care industry, General interest, News, opinion and commentary
Abstract

MONTCLAIR: Hackensack Meridian Health Mountainside Medical Group has issued the following press release: Mountainside Medical Group announced today the addition of three new physicians, Pulmonologist Juhayna Davis, M.D., Endocrinologist Anjali [...]

Published
2018

49. Fisher & Paykel Healthcare Corporation Limited: New Research on COPD Patients in Home using FPH myAirvo

Subjects
Fisher & Paykel Healthcare Corporation Ltd., NZX Ltd., Securities industry, Chronic obstructive lung disease -- Care and treatment, Medical equipment industry, Medical research, Securities industry, General interest, News, opinion and commentary
Abstract

Wellington: NZX Limited (NZSX) has issued the following announcement: Fisher & Paykel Healthcare Corporation Limited announced today that new research has been published in the International Journal of COPD which [...]

Published
2018

50. Chronic Obstructive Pulmonary Disease: 2018 Pipeline Highlights - ResearchAndMarkets.com

Subjects
Chronic obstructive lung disease -- Care and treatment, Company licensing agreement, General interest, News, opinion and commentary
Abstract

DUBLIN: Research and Markets has issued the following news release: The 'Chronic Obstructive Pulmonary Disease Pipeline Highlights - 2018' report has been added to ResearchAndMarkets.com's offering. 'Chronic Obstructive Pulmonary Disease [...]

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results